Department of Chemical Engineering and Materials Science, Yuan Ze University, Chung-Li, Taiwan.
Cytotherapy. 2013 Sep;15(9):1126-35. doi: 10.1016/j.jcyt.2013.04.002. Epub 2013 Jun 13.
The number of hematopoietic stem cells (HSCs) is critical for transplantation. The ex vivo expansion of mobilized peripheral blood (MPB) HSCs is of clinical value for reconstitution to meet clinical need.
This study proposed a simple, defined, stromal-free and serum-free culture system (SF-HSC medium) for clinical use, which is composed of Iscove's modified Dulbecco's medium, cytokine cocktails and serum substitutes. This study also characterized the cellular properties of expanded MPB CD133(+) HSCs from patients with hematologic malignancies and healthy donors by surface antigen, colony-forming cell, long-term culture-initiating cell, gene expression and in vivo engraftment assays.
The expanded fold values of CD45(+) white blood cells and CD34(+), CD133(+), CD34(+)CD38(-), CD133(+)CD38(-), CD34(+)CD133(+), colony-forming and long-term culture-initiating cells at the end of 7-day culture from CD133(+) MPB of hematologic malignancies were 9.4-fold, 5.9-fold, 4.0-fold, 35.8-fold, 21.9-fold, 3.8-fold, 11.8-fold and 6.7-fold, and values from healthy donor CD133(+) MPB were 20.7-fold, 14.5-fold, 8.5-fold, 83.8-fold, 37.3-fold, 6.2-fold, 19.1-fold and 14.6-fold. The high enrichment of CD38(-) cells, which were either CD34(+) or CD133(+), sustained the proliferation of early uncommitted HSCs. The expanded cells showed high levels of messenger RNA expression of HOBX4, ABCG2 and HTERT and had the in vivo ability to re-populate NOD/SCID mice.
Our results demonstrated that an initial, limited number of MPB CD133(+) HSCs could be expanded functionally in SF-HSC medium. We believe that this serum-free expansion technique can be employed in both basic research and clinical transplantation.
造血干细胞(HSCs)的数量对移植至关重要。动员外周血(MPB)HSCs 的体外扩增对于满足临床需求的重建具有临床价值。
本研究提出了一种简单、定义明确、无基质和无血清的培养系统(SF-HSC 培养基),由 Iscove 的改良 Dulbecco 培养基、细胞因子鸡尾酒和血清替代品组成。本研究还通过表面抗原、集落形成细胞、长期培养起始细胞、基因表达和体内植入实验,对来自血液系统恶性肿瘤患者和健康供体的扩增 MPB CD133(+)HSCs 的细胞特性进行了表征。
在第 7 天培养结束时,CD133(+)MPB 来自血液系统恶性肿瘤患者的 CD45(+)白细胞和 CD34(+)、CD133(+)、CD34(+)CD38(-)、CD133(+)CD38(-)、CD34(+)CD133(+)、集落形成和长期培养起始细胞的扩增倍数分别为 9.4 倍、5.9 倍、4.0 倍、35.8 倍、21.9 倍、3.8 倍、11.8 倍和 6.7 倍,而来自健康供体 CD133(+)MPB 的扩增倍数分别为 20.7 倍、14.5 倍、8.5 倍、83.8 倍、37.3 倍、6.2 倍、19.1 倍和 14.6 倍。高比例的 CD38(-)细胞,无论是 CD34(+)还是 CD133(+),维持了早期未分化 HSCs 的增殖。扩增细胞表现出高水平的 HOBX4、ABCG2 和 HTERT 的信使 RNA 表达,并具有在 NOD/SCID 小鼠体内重新定植的能力。
我们的结果表明,初始数量有限的 MPB CD133(+)HSCs 可以在 SF-HSC 培养基中进行功能性扩增。我们相信,这种无血清扩增技术可以应用于基础研究和临床移植。